ELQ-300

ELQ-300
Names
	Preferred IUPAC name 6-Chloro-7-methoxy-2-methyl-3-{4-[4-(trifluoromethoxy)phenoxy]phenyl}quinolin-4(1H)-one
Identifiers
CAS Number	1354745-52-0;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2431810;
ChemSpider	28540481;
PubChem CID	67016608;
	InChI InChI=1S/C24H17ClF3NO4/c1-13-22(23(30)18-11-19(25)21(31-2)12-20(18)29-13)14-3-5-15(6-4-14)32-16-7-9-17(10-8-16)33-24(26,27)28/h3-12H,1-2H3,(H,29,30) Key: WZDNKHCQIZRDKW-UHFFFAOYSA-N; InChI=1/C24H17ClF3NO4/c1-13-22(23(30)18-11-19(25)21(31-2)12-20(18)29-13)14-3-5-15(6-4-14)32-16-7-9-17(10-8-16)33-24(26,27)28/h3-12H,1-2H3,(H,29,30) Key: WZDNKHCQIZRDKW-UHFFFAOYAI;
	SMILES Cc1c(c(=O)c2cc(c(cc2[nH]1)OC)Cl)c3ccc(cc3)Oc4ccc(cc4)OC(F)(F)F;
Properties
Chemical formula	C24H17ClF3NO4
Molar mass	475.85 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

ELQ-300 is an experimental antimalarial medication. It is the first entry in a new class of antimalarials known as 4-quinolone-3-diarylethers.^[1]

ELQ-300 acts as an inhibitor of the mitochondrial cytochrome bc₁ complex (complex III in the electron transport chain) - A mechanism shared with some of the most potent fungicides known, the strobilurins.^[1] In preclinical studies with mice, ELQ-300 was found to be highly active against Plasmodium falciparum and Plasmodium vivax at all life cycle stages that play a role in the transmission of malaria, and to have good oral bioavailability.^[1]

References[]

^ ^a ^b ^c Nilsen A; et al. (2013). "Quinolone-3-diarylethers: a new class of antimalarial drug". Science Translational Medicine. 5 (177): 177ra37. doi:10.1126/scitranslmed.3005029. ISSN 1946-6234. PMC 4227885. PMID 23515079.

ELQ-300

References[]

Further reading[]